The Week in Review: SFDA’s Green Channel Allows Speeded-up Approval

Xian-Janssen launched Dacogen, a myelodysplastic syndrome treatment, based on ex-China clinical trials, after receiving SFDA approval through the Green Channel; GlaxoSmithKline will sell generics from Dr. Reddy's Labs in emerging markets; AlphaRx will receive research services from Venturepharm; two China biotechs, Sinovac Biotech and Hualan Biological Engineering, began clinical trials of swine flu vaccines; Mindray Medical reviewed its new medical product offerings; American Oriental Bioengineering (广西博科药业) was selected as one of the "Top 20 Most Competitive Public Pharmaceutical Companies in China"; and Sundia MediTech Company was named a Top 100 Fast-growth Outsourcing Service Provider. More details... Stock Symbols: (NYSE: GSK) (NYSE: RDL) (OTCBB: ALRX) (NYSE Amex: SVA) (NYSE: MR) (NYSE: AOB)